Femasys Inc. (FEMY) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated April 18, 2023, details a material definitive agreement entered into by Femasys Inc., a Delaware corporation. The filing reports on a registered direct offering and a concurrent private placement of equity securities.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $3.9 million.
- Net Proceeds: Approximately $3.4 million after deducting placement agent fees, expenses, and estimated offering costs.
- Securities Issued:
- 1,318,000 shares of Common Stock.
- Pre-funded warrants to purchase up to 1,878,722 shares of Common Stock.
- Common warrants to purchase up to 3,196,722 shares of Common Stock.
- Offering Prices: $1.22 per Share and associated Common Warrant; $1.2199 per Pre-Funded Warrant and associated Common Warrant.
- Placement Agent Compensation: 7.5% cash fee, 1.0% management fee, $75,000 expense allowance, $15,950 clearing fees, and warrants to purchase 191,803 shares.
Material Changes and Strategic Actions
The Company entered into a Securities Purchase Agreement to raise capital for general corporate purposes. Concurrently, effective April 18, 2023, the Company suspended its "at-the-market" sales program and terminated the continuous offering under its existing Equity Distribution Agreement. The Company agreed to a 45-day lock-up on new issuances of Common Stock and a one-year restriction on entering into variable rate transactions.
Outlook, Risks, and Management Commentary
The Company intends to use the net proceeds for general corporate purposes. The filing notes that the Common Warrants and Placement Agent Warrants are unregistered and offered pursuant to Section 4(a)(2) of the Securities Act and/or Regulation D. The Placement Agent Warrants are immediately exercisable at $1.525 per share with a five-year term. The Common Warrants are immediately exercisable at $1.095 per share with a five-and-a-half-year term.
Key Facts for Investor Verification
- Verify the final closing date and actual net proceeds received, as the filing states "expected" figures.
- Confirm the dilution impact of the 3,196,722 Common Warrants and 1,878,722 Pre-Funded Warrants on existing shareholders.
- Monitor the status of the suspended "at-the-market" sales program and any future filings to reactivate it.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific termination provisions and representations.